 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
25 News |  |
- | NATDAC (daclatasvir) / NATCO, Hetero
Journal: Predictive Potential Of Il28b Gene In Hcv Patients, Resistant To Daclatasvir And Sofosbuvir In KPK Population. (Pubmed Central) - Mar 1, 2024
In rs12979860 T/C model, genotype of IL28-B in the responder and resistant group significantly varies at p-value =0.00572. We conclude that in SNP at rs12979860, CC genotype is associated with clearance of HCV, while CT genotype was more prevalent in the resistant group and associated with chronicity.
- Transformer Based Deep Learning Method Reveals Novel Drugs and Comorbidity Associations in Pulmonary Arterial Hypertension (San Diego Convention Center, Room 28C-E (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_8217;
Transformer-based Deep Learning methods can capture embedded patterns within heterogeneous biomedical data and predict clinical associations in PAH. Our proposed Deep Learning model shows promise to identify established as well as novel PAH associations and reveal potential causal relationships in PAH.
- | NATDAC (daclatasvir) / NATCO, Hetero
Observational data, Journal: HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol. (Pubmed Central) - Dec 23, 2023
P=N/A
Data on incidence risk factors will allow us to model and incorporate heterogeneity of risk and how that affects screening and treatment strategies. These data will identify any gaps in current test-and-treat programs to achieve HCV elimination in Pakistan.
- | NATDAC (daclatasvir) / NATCO, Hetero
Journal: Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study. (Pubmed Central) - Jun 2, 2023
All were treated with DAAs for 12 weeks (5 with Paritaprevir-Ombitasvir-Ritonavir-Dasabuvir, 3 with Sofosbuvir-Ledipasvir, 1 with Sofosbuvir-Ribavirin, 1 with Sofosbuvir-Daclatasvir, 1 with Sofosbuvir-Velpatasvir) and 100% achieved SVR12...Our study shows that viral eradication obtained with DAA is associated with a trend in restoring the heterogeneity of ?-diversity and in reducing the percentage of potentially pathogenic microbial species, although this benefit is less evident in patients with cirrhosis. Further studies with larger sample size are needed to confirm these data.
- || Daklinza (daclatasvir) / BMS, NATDAC (daclatasvir) / NATCO, Hetero
Retrospective data, Review, Journal: Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis. (Pubmed Central) - Nov 22, 2022
Patients on SOF/velpatasvir±ribavirin achieved a significantly higher SVR (91.0%, 95% CI: 87.7-93.9) than that of SOF/ledipasvir±ribavirin [(86.3%, 95% CI: 84.6-87.8); p=0.004)], or on SOF/daclatasvir±ribavirin (82.4%, 95% CI: 78.2-86.2%; p<0.001)...There was no publication bias. The analysis found that 12 weeks of SOF/velpatasvir without ribavirin is the preferred therapy, with a significantly higher SVR compared with other SOF-based regimens in decompensated HCV patients.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, NATDAC (daclatasvir) / NATCO, Hetero, Vemlidy (tenofovir alafenamide) / Gilead
Journal, Real-world evidence: Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. (Pubmed Central) - Apr 19, 2022
The analysis found that 12 weeks of SOF/velpatasvir without ribavirin is the preferred therapy, with a significantly higher SVR compared with other SOF-based regimens in decompensated HCV patients. Similar to the observation made in HIV-negative patients, sustained virologic response 12 wk off-therapy with DAAs is high in PLWH coinfected with HCV-6.
- || NATDAC (daclatasvir) / NATCO, Hetero
Clinical, Review, Journal: Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. (Pubmed Central) - Feb 8, 2022
Although select antivirals have exhibited efficacy to improve clinical outcomes in COVID-19 patients, none demonstrated efficacy in reducing mortality. Larger RCTs are needed to conclusively establish efficacy.
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Retrospective data, Review, Journal: Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. (Pubmed Central) - Jan 16, 2021
Hydroxychloroquine did not provide clinical benefits while posing cardiac safety risks when combined with azithromycin, especially in the vulnerable population. Only 29% of current evidence on pharmacological management of COVID-19 is supported by moderate or high certainty and can be translated to practice and policy; the remaining 71% are of low or very low certainty and warrant further studies to establish firm conclusions.
- || Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie, daclatasvir/asunaprevir (BMS-60032/BMS-790052) / BMS
Retrospective data, Review, Journal: Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. (Pubmed Central) - Dec 19, 2020
Overall, SVR was lower in HCC compared to non-HCC patients, especially in those with active HCC though heterogeneity was high. Continued efforts are needed to aggressively screen, diagnose and treat HCC to ensure higher CHC cure rates.
- NATDAC (daclatasvir) / NATCO, Hetero
[VIRTUAL] ON-GOING REGISTRY TO UNDERSTAND PATIENT CHARACTERISTICS AND TREATMENT OUTCOMES IN ADULTS WITH CHRONIC HEPATITIS C INFECTION ACROSS ASIA AND AFRICA () - Oct 11, 2020 - Abstract #AASLD2020AASLD_882;
In this on-going registry of patients with Chronic HCV, sofosbuvir based regimens were effective in the heterogeneous, highly admixed populations across Asia and Africa. Policies should encourage treatment for all Chronic HCV infected patients with sofosbuvir based regimens in Asia and Africa.
- || paritaprevir/ritonavir (ABT-450/r) / AbbVie, Daklinza (daclatasvir) / BMS
Clinical, Journal, Real-World Evidence: Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. (Pubmed Central) - Sep 30, 2020
Policies should encourage treatment for all Chronic HCV infected patients with sofosbuvir based regimens in Asia and Africa. SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries.
- || velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS
Clinical, Journal: Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. (Pubmed Central) - May 23, 2020
The lower rates of SVR in patients infected with subtype 4r are related to the frequent preexistence at treatment baseline and subsequent selection by DAA treatment of both NS5A and NS5B S282 RASs. Our study suggests that these patients should be identified and receive a triple DAA combination regimen as first-line treatment.
- | Sunvepra (asunaprevir) / BMS, paritaprevir/ritonavir (ABT-450/r) / AbbVie, Daklinza (daclatasvir) / BMS
Retrospective data, Review, Journal: Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: systematic review and meta-analysis. (Pubmed Central) - May 5, 2019
Our study suggests that these patients should be identified and receive a triple DAA combination regimen as first-line treatment. Direct-acting antiviral treatment is highly effective and well-tolerated in liver transplant recipients with recurrent GT1 HCV infection.
- | Trial completion, Combination therapy: Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] (clinicaltrials.gov) - Mar 15, 2019
P2/3, N=150, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Direct-acting antiviral treatment is highly effective and well-tolerated in liver transplant recipients with recurrent GT1 HCV infection. Recruiting --> Completed
- | New P2/3 trial, Combination therapy: Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] (clinicaltrials.gov) - Mar 29, 2018
P2/3, N=150, Recruiting, Sponsor: Johns Hopkins Bloomberg School of Public Health